ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV
21.12.2019 11:46:00 EET | Business Wire | Press release
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding its application for cabotegravir and rilpivirine long-acting regimen for treatment of HIV-1 infection in virologically suppressed adults.
The reasons given in the CRL relate to Chemistry Manufacturing and Controls (CMC). There have been no reported safety issues related to CMC and there is no change to the safety profile of the products used in clinical trials to date. ViiV Healthcare will work closely with the FDA to determine the appropriate next steps for this New Drug Application.
Cabotegravir is an integrase strand transfer inhibitor developed by ViiV Healthcare and rilpivirine is a non-nucleoside reverse transcriptase inhibitor developed by Janssen Sciences Ireland UC. The cabotegravir and rilpivirine long-acting regimen is an investigational product and not approved anywhere in the world.
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.
For more information on the company, its management, portfolio, pipeline and commitment, please visit www.viivhealthcare.com.
About GSK
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2018.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The person responsible for arranging the release of this announcement on behalf of GSK is V.A. Whyte, Company Secretary.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191221005008/en/
Contact information
ViiV Healthcare Media enquiries:
Audrey Abernathy, +1 919 605 4521
Stephen Rea, +44 (0) 78 8126 9009
GSK Global Media enquiries:
Simon Steel, +44 (0) 20 8047 5502
Kathleen Quinn, +1 202 603 5003
Analyst/Investor enquiries:
Sarah Elton-Farr, +44 (0) 20 8047 5194
Danielle Smith, +44 (0) 20 8047 0932
James Dodwell, +44 (0) 20 8047 2406
Jeff McLaughlin, +1 215 751 7002
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HTEC and Embotech Partner to Scale Deployment of Autonomous Driving Solutions for Industrial Logistics7.7.2026 13:39:00 EEST | Press release
HTEC, a global technology and AI engineering company headquartered in Silicon Valley, and Embotech, a global leader in safety-certified Level 4 autonomous driving solutions for industrial logistics, today announced a strategic partnership to scale deployment of Embotech's autonomous driving solutions across vehicle platforms, customer programmes and industrial sites. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707870943/en/ HTEC, a global technology and AI engineering company headquartered in Silicon Valley, and Embotech, a global leader in safety-certified Level 4 autonomous driving solutions for industrial logistics, today announced a strategic partnership to scale deployment of Embotech's autonomous driving solutions across vehicle platforms, customer programmes and industrial sites. The partnership comes as Embotech’s proven autonomous driving solutions are being adopted across a growing number of vehicle platforms
Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile7.7.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing Phase 3 COMP006 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD) which confirm COMP360’s rapid onset and durable profile. The 26-week findings in nearly 600 patients build on previously reported results from the first Phase 3 trial, COMP005, which demonstrated rapid onset and durable response to at least 6 months, with a generally well-tolerated and safe profile in people living with TRD. The COMP360 Phase 3 program participants represent a highly chronic TRD population. In COMP006, participants had current depressive episodes lasting on average over three years and an average of more than six lifetime depressive episodes. Within the context of this severe population, 39% of participants in the 25 mg arm achieved a clinically m
Private Department of Sheikh Mohammed bin Khalid Al Nahyan Invests in MidOcean Energy and Forms Strategic Partnership with EIG7.7.2026 13:16:00 EEST | Press release
The Private Department of Sheikh Mohammed bin Khalid Al Nahyan (the “Private Department”) has today committed to invest $1.13bn in MidOcean Energy (“MidOcean” or the “Company”), a liquefied natural gas (LNG) company formed and managed by EIG. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707259928/en/ In parallel with the investment, the Private Department and EIG have established a strategic partnership focused on capital aggregation, investment origination, and the development of institutional investment opportunities across the United Arab Emirates and selected regional markets. The Investment in MidOcean represents the Private Department’s entry into the global LNG sector and marks the launch of a broader strategic relationship with EIG, a global energy and infrastructure investment firm. Through this partnership, the parties intend to collaborate on future investment opportunities across the energy and related infra
Infobip Research Reveals Businesses Scaling AI-Powered Defenses to Counter Surge in Automated Fraud7.7.2026 12:55:00 EEST | Press release
New research from global AI-first cloud communications platform Infobip reveals a growing surge in AI-powered fraud and enterprise defenses. Analyzing billions of interactions globally, Infobip’s 2026 Fraud & Security Report highlights a year of dramatic contrasts. There have been record volumes of blocked fraudulent traffic alongside the rapid scaling of intelligent, AI-powered defenses. The report reveals that while fraudsters are using AI to scale and personalize harmful messaging, leading to a 77% increase in detected threats, businesses are responding in kind. Adoption of AI-powered fraud detection grew by 71% year-on-year, while pattern-based detection increased by 105%, underscoring a shift toward adaptive security. The report demonstrates the impact of AI-first security. Leading UK-based clothing brand NEXT is leveraging Infobip Signals, an AI and machine learning-powered solution designed to combat artificially inflated traffic, helping protect customers against fraud. Raz Raz
Santander Financial Crime Transformation Leader Joins ThetaRay to Drive Enterprise AI Adoption7.7.2026 11:00:00 EEST | Press release
ThetaRay, a leader in AI infrastructure for financial crime compliance, today announced the appointment of Luis Pinedo as Chief Strategic Customers Officer. Previously Pinedo was Group VP of Compliance at Santander Bank, where during his 16-year tenure, he led global Financial Crime Compliance (FCC) transformation initiatives across operating models, processes, and technology platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707359150/en/ Luis Pinedo joins ThetaRay as Chief Strategic Customers Officer. In his new role, Pinedo will bring key perspectives from tier-one banking operational challenges to ThetaRay’s product development and design. He will lead strategic customer engagement as well as product strategy across ThetaRay’s entire compliance platform, including Transaction Monitoring, Screening, Customer Risk Assessment, and Agentic Investigations. The appointment comes at a critical time in the RegTech indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom